Written and maintained by CASRAI Editorial Board
Last updated
In clinical research, ePRO (electronic Patient-Reported Outcome) refers to the digital capture of health status, symptom severity, functional capability, or health-related quality of life data reported directly by a study participant—without amendment or interpretation by a clinician or anyone else—using smartphones, tablets, or web portals. Across Phase I–IV drug, biologic, and medical device investigations, ePRO clinical trials architectures have largely replaced paper symptom diaries to prevent retrospective back-filling, enforce real-time protocol time windows, and feed regulatory-grade primary and secondary endpoint data directly into electronic data capture (EDC) platforms such as Medidata Rave and OpenClinica.
To understand how ePRO software is regulated and deployed, clinical data managers and trial sponsors must distinguish between ePRO and the broader electronic Clinical Outcome Assessment (eCOA) taxonomy, evaluate Bring Your Own Device (BYOD) versus sponsor-provisioned hardware, and satisfy FDA 21 CFR Part 11 and ISPOR measurement equivalence standards.
What Is ePRO in Clinical Trials?
Under the U.S. Food and Drug Administration (FDA) 2009 guidance Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims and the FDA-NIH BEST (Biomarkers, EndpointS, and other Tools) glossary, a patient-reported outcome (PRO) is any report of the status of a patient’s health condition that comes directly from the patient. An electronic patient-reported outcome (ePRO) is a PRO collected via an electronic device rather than a paper form.
Why did regulatory authorities and sponsors transition from paper diaries to ePRO? In a landmark study published in the BMJ (Stone et al., 2002), researchers equipped paper pain diaries with hidden photosensors that recorded when the binder was actually opened and compared them against time-stamped electronic diaries:
- Patients using paper diaries reported 90% compliance, but photosensor logs revealed that actual contemporaneous compliance was only 11%, with 75% of participants engaging in “parking-lot compliance” (hoarding and back-filling days of entries immediately before a clinic visit) or forward-filling future dates.
- Patients using electronic diaries with enforced time-window lockouts achieved 94% actual contemporaneous compliance.
ePRO vs. eCOA: How the Terms Differ
A frequent question in clinical trial protocol design is ePRO vs. eCOA (or eCOA vs. ePRO). The two terms are not synonymous; rather, eCOA is the overarching umbrella category, and ePRO is one of its four subsets:
| Electronic Assessment Type | Full Name | Who Enters the Data? | Clinical Trial Examples |
|---|---|---|---|
| eCOA (Umbrella Term) | Electronic Clinical Outcome Assessment | Patient, clinician, non-clinical observer, or automated performance task | All four categories below (ePRO + eClinRO + eObsRO + ePerfO) |
| ePRO (Subset of eCOA) | Electronic Patient-Reported Outcome | The study participant directly, without clinician or caregiver interpretation | Daily Numeric Pain Rating Scale (NPRS), PROMIS-29, EQ-5D-5L, EORTC QLQ-C30, electronic seizure or migraine diaries |
| eClinRO (Subset of eCOA) | Electronic Clinician-Reported Outcome | A trained healthcare professional using clinical judgment after observing the patient | ADAS-Cog (Alzheimer’s disease), Hamilton Depression Rating Scale (HAM-D), Psoriasis Area and Severity Index (PASI) |
| eObsRO (Subset of eCOA) | Electronic Observer-Reported Outcome | A parent, caregiver, or non-clinical observer watching observable behaviors in patients who cannot self-report (e.g., infants) | Pediatric behavioral pain scales, caregiver daily vomiting/stool episode logs |
| ePerfO (Subset of eCOA) | Electronic Performance Outcome | Standardized active task performed by the patient and scored objectively | 6-Minute Walk Test (6MWT), Nine-Hole Peg Test, digital cognitive reaction-time tasks |
BYOD vs. Provisioned Devices in ePRO Software Deployment
Modern ePRO software supports three hardware deployment architectures across site-based, hybrid, and decentralized clinical trials (DCTs):
- Bring Your Own Device (BYOD): Participants download the study’s validated iOS or Android ePRO mobile app onto their personal smartphone or access a responsive web portal. BYOD eliminates the need for patients to carry a second phone, increases diary completion rates, and removes global hardware shipping and customs logistics.
- Sponsor-Provisioned Devices: A dedicated, locked-down smartphone or clinic tablet (managed via Mobile Device Management [MDM] with pre-configured cellular data) is shipped to the site or patient. Provisioned devices guarantee uniform screen dimensions and operating system versions.
- Hybrid (BYOD + Provisioned Backup): Recommended by the FDA’s decentralized clinical trials guidance to prevent socioeconomic selection bias—participants with compatible smartphones use BYOD, while participants without compatible personal devices receive a provisioned handset so no eligible patient is excluded.
ISPOR Paper-to-ePRO Equivalence and Migration Standards
When a validated paper questionnaire is migrated onto an ePRO screen, sponsors must demonstrate that the electronic format does not alter how patients interpret or respond to items. The ISPOR ePRO Good Research Practices Task Force (Coons et al., 2009; updated for BYOD by Byrom et al., 2019) classifies migrations into three modification levels:
- Minor Modification (Best Practice: One Item Per Screen): Reformatting a paper questionnaire to display a single item per screen without altering item wording, recall period, or response options (and eliminating vertical scrolling). Requires cognitive debriefing and usability testing (typically in 5 to 10 representative patients).
- Moderate Modification: Changing item presentation order, splitting multi-part questions, or modifying graphic scales in ways that could shift response distributions. Requires quantitative equivalence testing (e.g., randomized crossover study evaluating intraclass correlation coefficients [ICC]).
- Substantial Modification: Rewriting item stems, changing a visual analog scale to a Likert scale without prior validation, or altering the recall window. Requires full psychometric revalidation as a de novo instrument.
FDA 21 CFR Part 11, ALCOA+, and CDISC Data Standards
Because ePRO entries serve as primary electronic source data (eSource), ePRO software must comply with FDA 21 CFR Part 11, the FDA’s final guidance Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers (October 2024), and ALCOA+ principles:
- Contemporaneous Time-Windowed Capture: Episodic or daily ePRO diaries open only during protocol-defined windows (for example, 18:00 to 23:59 local time for an evening diary) and lock automatically afterward, preventing retrospective data fabrication.
- Attribution and Non-Repudiation: Each participant authenticates with a unique PIN or biometric credential tied to their subject ID, ensuring the ePRO response is attributable solely to the enrolled participant.
- Immutable Audit Trails: Any administrative correction (submitted via a formal Data Clarification Form [DCF] signed by the participant and investigator, since sites may never arbitrarily alter a patient’s subjective rating) is recorded in a computer-generated, time-stamped audit trail with the reason for change.
- Interoperability (CDISC ODM and SDTM
QSDomain): ePRO platforms export metadata and responses via CDISC ODM-XML v1.3.2/v2.0 and map scored questionnaires directly into the CDISC Study Data Tabulation Model (SDTM) Questionnaires (QS) or Disease Response/Clinical Classification (RS/FT) domains for FDA and EMA submission.
Frequently Asked Questions
What is ePRO in clinical trials?
In clinical trials, ePRO (electronic Patient-Reported Outcome) is the direct digital collection of symptom, functional, and quality-of-life data from study participants using mobile apps, provisioned handheld devices, or web portals without interpretation by a clinician. ePRO software enforces protocol recall windows, eliminates paper “parking-lot compliance” (back-filling), and generates 21 CFR Part 11-compliant electronic source (eSource) data.
What is the difference between ePRO and eCOA?
eCOA (electronic Clinical Outcome Assessment) is the broad umbrella term for all digital outcome assessments in a clinical trial, encompassing four distinct subtypes: ePRO (patient-reported), eClinRO (clinician-reported), eObsRO (observer/caregiver-reported), and ePerfO (performance outcomes). Every ePRO is an eCOA, but not every eCOA is an ePRO.
